Incannex Healthcare Limited Sponsored ADR (IXHL)
NASDAQ:IXHL
Want to see IXHL full AI Analyst Report?
IXHL Stock Chart & Stats
$0.39
-$0.11(-5.37%)
At close: 4:00 PM EST
$0.39
-$0.11(-5.37%)
Day’s Range― - ―
52-Week Range$2.49 - $49.80
Previous CloseN/A
Volume10.98K
Average Volume (3M)361.38K
Market Cap
$40.08M
Enterprise Value-$35.86M
Total Cash (Recent Filing)$68.90M
Total Debt (Recent Filing)$163.00K
Price to Earnings (P/E)―
Beta3.71
Next Earnings
Sep 02, 2026EPS Estimate
-0.6Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.29
Shares Outstanding11,964,554
10 Day Avg. Volume219,626
30 Day Avg. Volume361,379
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)0.55
Price to Sales (P/S)86.40
P/FCF Ratio-0.59
Enterprise Value/Market Cap-0.89
Enterprise Value/Revenue-538.34
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda0.79
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-1.2
Revenue Forecast (FY)$700.00K
Bulls Say, Bears Say
Bulls Say
Strong Cash Position And No DebtA ~ $75M cash balance with no debt provides durable funding runway to complete mid‑late stage trials and preserves optionality for Phase 3 timing and commercialization planning. This liquidity reduces near‑term dilution risk and supports execution without immediate financing pressure.
Advancing Lead Program Into Dose‑optimization StudyInitiation of the DReAMzz dose‑optimization study and Fast Track status materially de‑risks the IHL‑42X development pathway. Completed manufacturing and site setup demonstrate operational readiness and improve probability of a streamlined Phase 3, underpinning long‑term commercial potential.
Scientific Partnerships And External ValidationAASM engagement and sponsorship strengthen scientific credibility, support investigator relationships and improve trial recruitment and guideline awareness. Coupled with award recognition, these ties increase the likelihood of clinical adoption and durable market positioning in sleep medicine.
Bears Say
Persistent Negative Cash FlowSustained negative operating and free cash flow (≈ -$12.5M in 2025) indicates ongoing cash burn that will pressure capital resources absent material commercial revenue. Even with improved burn, the company remains dependent on external funding to sustain development beyond current milestones.
Continued Heavy Losses And Weak MarginsDeep negative margins and recurring net losses mean the firm is not generating returns on equity and faces a long path to profitability. This structural lack of earnings power constrains reinvestment capacity and elevates execution risk until commercial revenues become meaningful.
Limited Commercial Revenue; Reliance On Equity FundingMinimal commercial revenue (only ~$0.09M in 2025) forces dependence on equity raises for trial funding. Terminating the ATM and using discrete offerings provides visibility but underscores structural reliance on external capital until a commercial product generates sustainable revenue.
Incannex Healthcare Limited Sponsored ADR News
IXHL FAQ
What was Incannex Healthcare Limited Sponsored ADR’s price range in the past 12 months?
Incannex Healthcare Limited Sponsored ADR lowest stock price was $2.49 and its highest was $49.80 in the past 12 months.
What is Incannex Healthcare Limited Sponsored ADR’s market cap?
Incannex Healthcare Limited Sponsored ADR’s market cap is $40.08M.
When is Incannex Healthcare Limited Sponsored ADR’s upcoming earnings report date?
Incannex Healthcare Limited Sponsored ADR’s upcoming earnings report date is Sep 02, 2026 which is in 94 days.
How were Incannex Healthcare Limited Sponsored ADR’s earnings last quarter?
Incannex Healthcare Limited Sponsored ADR released its earnings results on Mar 02, 2026. The company reported -$0.6 earnings per share for the quarter, the consensus estimate of -$0.6 by $0.
Is Incannex Healthcare Limited Sponsored ADR overvalued?
According to Wall Street analysts Incannex Healthcare Limited Sponsored ADR’s price is currently Overvalued.
Does Incannex Healthcare Limited Sponsored ADR pay dividends?
Incannex Healthcare Limited Sponsored ADR does not currently pay dividends.
What is Incannex Healthcare Limited Sponsored ADR’s EPS estimate?
Incannex Healthcare Limited Sponsored ADR’s EPS estimate is -0.6.
How many shares outstanding does Incannex Healthcare Limited Sponsored ADR have?
Incannex Healthcare Limited Sponsored ADR has 11,964,554 shares outstanding.
What happened to Incannex Healthcare Limited Sponsored ADR’s price movement after its last earnings report?
Incannex Healthcare Limited Sponsored ADR reported an EPS of -$0.6 in its last earnings report, expectations of -$0.6. Following the earnings report the stock price went down -9.906%.
Which hedge fund is a major shareholder of Incannex Healthcare Limited Sponsored ADR?
Currently, no hedge funds are holding shares in IXHL
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Incannex Healthcare Limited Sponsored ADR Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Blogger Sentiment
Bullish
IXHL Sentiment 70%
Sector Average ―
Sector Average ―
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.3%
Last 30 Days ▼ 5.1%
Last 30 Days ▼ 5.1%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-49.24%
12-Months-Change
Fundamentals
Return on Equity
-122.57%
Trailing 12-Months
Asset Growth
395.67%
Trailing 12-Months
Company Description
Incannex Healthcare Limited Sponsored ADR
Incannex Healthcare Limited engages in the research, development, and sale of medicinal cannabinoid products in Australia. It offers pharmaceutical grade cannabinoid products under the Incannex brand name. The company's products include IHL-42X, which is in Phase II clinical trials for obstructive sleep apnea; IHL-216A for traumatic brain injury; and IHL-675A, a combination of hydroxychloroquine and cannabidiol for the prevention and treatment of inflammatory lung conditions, such as acute respiratory distress syndrome, chronic obstructive pulmonary disease, asthma, and bronchitis, as well as rheumatoid arthritis and inflammatory bowel diseases. It has partnership with The Alfred Hospital and Novotech on IHL-42X clinical program for obstructive sleep apnea; and Monash Trauma Group at the Department of Neuroscience, Monash University to conduct a study on the protective effect of IHL-216A in sports concussion. The company was formerly known as Impression Healthcare Limited and changed its name to Incannex Healthcare Limited in June 2020. Incannex Healthcare Limited was incorporated in 2001 and is based in Sydney, Australia.
Technical Analysis
Assertio Therapeutics
―
Cumberland Pharmaceuticals
―
China SXT Pharmaceuticals
―
Journey Medical Corp
―
BioAge Labs, Inc.
―
Ownership Overview
Currently, No data available
---